DocMorris AG (ZRSEF) Q4 2024 Earnings Call Transcript

2025-03-14 00:24:03 ET

DocMorris AG (ZRSEF)

Q4 2024 Earnings Conference Call

March 13, 2025 06:00 ET

Company Participants

Walter Hess - Chief Executive Officer

Daniel Wüest - Chief Financial Officer

Conference Call Participants

Olivier Calvet - UBS

Jan Koch - Deutsche Bank

Yannik Siering - Stifel

Urs Kunz - Research Partners

Gian Marco Werro - Zurcher KB

Michael Heider - Warburg Research

Christopher Johnen - HSBC

Presentation

Operator

Hello, ladies and gentlemen and welcome to the DocMorris AG 2024 Full Year Results and Outlook 2025. At this time, all participants have been placed on a listen-only mode. The floor will be open for questions following the presentation.

Let me now turn the floor over to your host, Walter Hess.

Walter Hess

Thank you very much and good morning to everybody to today's conference call. The full year results '24 will be presented by Daniel Wüest, our new CFO and myself. We will share insights and updates across all segments and provide a comprehensive overview of our business performance. So we will start with a business update, followed by a financial update and conclude with our outlook. Thereafter, we are looking forward to answering your questions.

Let us start with the highlights of last year. In 2024, we achieved significant milestones again. Since the introduction of CardLink in April '24, there has been a fivefold increase in new Rx customers. These new customers show significantly improved KPIs compared to our former TRx customers. We are very pleased to announce that in 2024, we reached profitability with our non-Rx business. It reflects our strategic efforts and the successful execution of the breakeven program over the last few years. Overall, there was a 7% increase in revenue with contributions from all business segments. And further, Teleclinic achieved a noteworthy milestone by doubling its revenues, demonstrating strong performance and attractive profitability metrics. And in conclusion and due to a really effective cash management, we reported a cash balance end of 2024 of CHF95 million.

On Slide number 5, we look forward to '25 with our strategic initiatives that are centered on, first of all, further expanding Rx growth with the customers who demonstrated already that they show significantly improved KPIs and favorable unit economics. With the new marketing campaign, Mach's dir Doc einfach, our objectives are besides further enhancing awareness, to increase consideration and drive conversion into eRx orders. The non-Rx business is expected to further grow profitably, thereby contributing to the future expansion of our eRx business. And also Teleclinic is continuing to achieve significant growth while also expanding its profitability margins. And finally, as you have read this morning, we will raise capital of about CHF200 million to support the Rx growth and safeguarding the refinancing of the convertible bond 2026....

Read the full article on Seeking Alpha

For further details see: